{"id":{"repo_id":"uwo","oai_identifier":"oai:uwo.scholaris.ca:20.500.14721/33763"},"canonical_url":"https://search.dev.ndltd.org/etd/uwo/oai:uwo.scholaris.ca:20.500.14721/33763","repository":{"repo_id":"uwo","name":"Western University","base_url":"https://uwo.scholaris.ca/server/oai/request"},"display":{"title":"Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastatin","abstract":"Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its effect through targeted accumulation in the liver. Current United States and Canadian dosing guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, we demonstrate for the first time that concomitant administration with food substantially reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian subjects. In mice lower plasma level was also noted with food 2 hours after an oral rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as opposed to on an empty stomach, does not significantly affect the cholesterol-lowering capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle pain/damage associated with high circulating statin levels, our findings have the potential to serve as a novel and simple strategy for mitigating statin myopathy risk.","abstract_html":"Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its effect through targeted accumulation in the liver. Current United States and Canadian dosing guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, we demonstrate for the first time that concomitant administration with food substantially reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian subjects. In mice lower plasma level was also noted with food 2 hours after an oral rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as opposed to on an empty stomach, does not significantly affect the cholesterol-lowering capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle pain/damage associated with high circulating statin levels, our findings have the potential to serve as a novel and simple strategy for mitigating statin myopathy risk.","abstract_has_math":false,"creators":["McLean, Cheynne C."],"institution":"The University of Western Ontario","degree_name":"M Sc","degree_level":null,"degree_discipline":"Physiology and Pharmacology","degree_department":null,"school":null,"contributors":[],"advisors":["Richard B. Kim"],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-05-25","date_published":"2016-05-25","updated_at":"2026-07-27T21:56:07Z","subjects":["rosuvastatin","HMG-CoA reductase inhibitors","oral pharmacokinetics","food effect","hepatic uptake transport","drug transporter pharmacogenetics"],"languages":["en_ca"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/20.500.14721/33763","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Richard B. Kim"]},{"key":"dc:creator","label":"Author","values":["McLean, Cheynne C."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-07-10T19:55:17Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-07-10T19:55:17Z"]},{"key":"dc:date.issued","label":"Date","values":["2016-05-25"]},{"key":"dc:publisher","label":"Institution","values":["The University of Western Ontario"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Physiology and Pharmacology"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M Sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["rosuvastatin","HMG-CoA reductase inhibitors","oral pharmacokinetics","food effect","hepatic uptake transport","drug transporter pharmacogenetics"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_ca"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/20.500.14721/33763"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."]},{"key":"dc:description.abstract","label":"Abstract","values":["Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its effect through targeted accumulation in the liver. Current United States and Canadian dosing guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, we demonstrate for the first time that concomitant administration with food substantially reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian subjects. In mice lower plasma level was also noted with food 2 hours after an oral rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as opposed to on an empty stomach, does not significantly affect the cholesterol-lowering capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle pain/damage associated with high circulating statin levels, our findings have the potential to serve as a novel and simple strategy for mitigating statin myopathy risk."]},{"key":"dc:title","label":"Title","values":["Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastatin"]}]}],"canonical_facts":{"dc:contributor.advisor":["Richard B. Kim"],"dc:creator":["McLean, Cheynne C."],"dc:date.accessioned":["2025-07-10T19:55:17Z"],"dc:date.available":["2025-07-10T19:55:17Z"],"dc:date.issued":["2016-05-25"],"dc:description":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."],"dc:description.abstract":["Rosuvastatin is commonly prescribed for the treatment of hypercholesterolemia and exerts its effect through targeted accumulation in the liver. Current United States and Canadian dosing guidelines indicate no preference for fed or fasted rosuvastatin administration. In this study, we demonstrate for the first time that concomitant administration with food substantially reduced mean plasma rosuvastatin exposure in healthy Canadian East Asian and Caucasian subjects. In mice lower plasma level was also noted with food 2 hours after an oral rosuvastatin dose, while liver concentration was unaffected. Moreover, through retrospective analysis of rosuvastatin patient data, we conclude that taking an oral dose with food as opposed to on an empty stomach, does not significantly affect the cholesterol-lowering capacity of rosuvastatin. Since a common adverse event noted with statin therapy is muscle pain/damage associated with high circulating statin levels, our findings have the potential to serve as a novel and simple strategy for mitigating statin myopathy risk."],"dc:identifier.uri":["https://hdl.handle.net/20.500.14721/33763"],"dc:language.iso":["en_ca"],"dc:publisher":["The University of Western Ontario"],"dc:subject":["rosuvastatin","HMG-CoA reductase inhibitors","oral pharmacokinetics","food effect","hepatic uptake transport","drug transporter pharmacogenetics"],"dc:title":["Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastatin"],"dc:type":["thesis"],"thesis:degree_discipline":["Physiology and Pharmacology"],"thesis:degree_name":["M Sc"]},"updated_at":"2026-07-27T21:56:07Z"}